FDA red and green lights: October 2024
October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.
Not so B-Fast for Roche
The focus for divarasib in second-line lung is now the head-to-head Krascendo-1 trial.
Zepzelca’s pivotal surprise
Jazz's somewhat low-key SCLC drug scores its biggest win yet.
Roche expands in KRAS
GDC-7035 enters the clinic, as does another bispecific against PD-L1 and VEGF.